Cannabinoids in movement disorders

Kluger, Benzi M.; Huang, Andrew Phillip

doi:10.1016/j.parkreldis.2022.08.014

Cited by 5 publications

(4 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cannabis can be used for two main medical uses, according to research (Hill et al,2019;Di Marzo & De Petrocellis, 2006). Clinical trials have validated the beneficial effect of Cannabis in a) spasticity from spinal cord injury or multiple sclerosis (Ianotti,2023), b) chronic pain, neuropathic pain (O´Brien et al,2023), c) movement disorders like Gilles de la Tourette syndrome, dystonia, and levodopa-induced dyskinesia (Kluger et al,2022), d) asthma (Jarjoui & Izbicki, 2020), and e) glaucoma, where it reduces aqueous humor production and protects nerves (Novack,2016). Cannabinoids show promise in controlled studies, but more research is necessary on their effectiveness and safety.…”

Section: Discussionmentioning

confidence: 99%

The Issue of Legalizing Cannabis: A Qualitative Analysis of the Student’s Public Discourse

Agalliu

2024

J. of Law and Sust. Develop.

View full text Add to dashboard Cite

Introduction: The objective of the present work is to analyze in a multidimensional view, Albania's Law No. 61/2023 on Cannabis legalization for its legal, applicability mechanisms, and economic challenges, assessing the readiness of the country, clarity, and impact on drug control. Method: The method of this study is quasi-experimental, and it is divided into two phases. The current study sample is two hundred students, of whom 120 (60%) were from the Faculty of Law and 80 (40%) from the University of Medical Sciences. The initial retrospective study (T1) was employed to identify the gaps in the legal education of law and assess the legislation’s stance. Five months later (T2) Medical Cannabis Juridical Education; Law enforcement capacities; and Social and Psychological impact identified as the key gaps were evaluated. Results: The students enrolled in the Law and Pharmacy program showed an improved understanding of the socio-psychological ramifications associated with the law implementation in Albania (t1 = 2; 7; t2 = 3.76; p < 0.001). Regressive results revealed an influence of Judicial and Psychoeducational training on the students' public opinion with an R-value model summary of 0,706 (70%). Conclusions: The findings of this study suggest that the legalization of Cannabis in Albania is a significant challenge for the country and continued follow-up and public training would increase public awareness and assertiveness toward the Law.

show abstract

Section: Discussionmentioning

confidence: 99%

The Issue of Legalizing Cannabis: A Qualitative Analysis of the Student’s Public Discourse

Agalliu

2024

J. of Law and Sust. Develop.

View full text Add to dashboard Cite

show abstract

“…Researchers have conducted investigations into the treatment effects of CBD/THC for age-related diseases such as Alzheimer’s disease [ 173 , 174 , 175 , 176 , 177 ], dementia [ 178 , 179 ], and Parkinson’s disease [ 180 , 181 , 182 , 183 , 184 ]. However, most of these studies either focus on the PD of CBD/THC and the clinical endpoint of the disease or combine all age groups when analyzing the PK results.…”

Section: Cbd/thc Studies In Special Populationsmentioning

confidence: 99%

CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

Qian,

Beers,

Jackson

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Cannabinoid use has surged in the past decade, with a growing interest in expanding cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) applications into special populations. Consequently, the increased use of CBD and THC raises the risk of drug–drug interactions (DDIs). Nevertheless, DDIs for cannabinoids, especially in special populations, remain inadequately investigated. While some clinical trials have explored DDIs between therapeutic drugs like antiepileptic drugs and CBD/THC, more potential interactions remain to be examined. This review summarizes the published studies on CBD and THC–drug interactions, outlines the mechanisms involved, discusses the physiological considerations in pharmacokinetics (PK) and DDI studies in special populations (including pregnant and lactating women, pediatrics, older adults, patients with hepatic or renal impairments, and others), and presents modeling approaches that can describe the DDIs associated with CBD and THC in special populations. The PK of CBD and THC in special populations remain poorly characterized, with limited studies investigating DDIs involving CBD/THC in these populations. Therefore, it is critical to evaluate potential DDIs between CBD/THC and medications that are commonly used in special populations. Modeling approaches can aid in understanding these interactions.

show abstract

“…The largest challenge in sorting through the evidence is variability in types of cannabinoid used ( 9 THC or CBD); the mode of administration (inhaled, vaporized, oils); variable doses and duration of use. Despite preclinical studies showing theoretical evidence for a role of cannabinoids in basal ganglia function, there remains low-level and conflicting clinical evidence of efficacy on motor symptoms, from patient-facing surveys and a small number of RCTs [30][31][32].…”

Section: Clinical Evidence: Motor Symptomsmentioning

confidence: 99%

Advice to People with Parkinson’s in My Clinic: Cannabis

de Freitas,

Fox

2024

Journal of Parkinson’s Disease

View full text Add to dashboard Cite

Cannabis (in all the varied methods of delivery) continues to garner significant attention as a potential therapeutic intervention for neurodegenerative disorders, including Parkinson’s disease (PD). The recent legalization of personal use of cannabis products in some parts of the world has increased this interest and with it, potential availability to many more people. However, such access has led to more questions than answers for both patients and health care professionals. These include what symptom(s) of PD will cannabis products treat; what dose; what type of cannabis product to use and what are the side effects?

show abstract

Cannabinoids in movement disorders

Cited by 5 publications

References 96 publications

The Issue of Legalizing Cannabis: A Qualitative Analysis of the Student’s Public Discourse

The Issue of Legalizing Cannabis: A Qualitative Analysis of the Student’s Public Discourse

CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

Advice to People with Parkinson’s in My Clinic: Cannabis

Contact Info

Product

Resources

About